News
![Could This Medicine Be the Next Winner for Novartis?: https://g.foolcdn.com/editorial/images/744947/a-patient-attends-a-doctor-appointment.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNjk3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e905c481e0c2cd257bd4f550754ad4b91e4bffc9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-patient-attends-a-doctor-appointment.jpg?locale=us)
Could This Medicine Be the Next Winner for Novartis?
Earlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug candidate remibrutinib for a skin condition known
![2 Top Biotech Stocks to Buy Right Now: https://g.foolcdn.com/editorial/images/743787/a-doctor-examines-a-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFJ4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7e6dfa3fccb8c74072d028455a42d9c5fe27d655/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-doctor-examines-a-patient.jpg?locale=us)
2 Top Biotech Stocks to Buy Right Now
Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend income. The trick is diversifying across top businesses in numerous industries to
![2 Stocks That Raised Their Guidance in July: https://g.foolcdn.com/editorial/images/740653/investor-checking-stocks-on-his-phone.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1JiYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ca5aeba9191afef1ebdb9b092f2f85797367b428/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-checking-stocks-on-his-phone.jpg?locale=us)
2 Stocks That Raised Their Guidance in July
One thing that can often drive up a stock's value is an increase in guidance. And two companies that recently boosted their projections for the year are Novartis (NYSE: NVS) and PepsiCo (NASDAQ:
![Should Income Investors Buy This Blue Chip Stock?: https://g.foolcdn.com/editorial/images/740451/a-customer-shops-at-a-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHhYYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0e0b1c6b6da0777fd19e49799059b70d7b8b5c99/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-customer-shops-at-a-pharmacy.jpg?locale=us)
Should Income Investors Buy This Blue Chip Stock?
For a dividend investor, generating enough income to become and stay financially independent (higher passive income than expenses) comes down in large part to the longevity of the businesses in an
![Why Novartis Stock Spiked Today: https://g.foolcdn.com/editorial/images/740239/healthcare.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL3RTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5fe043fab83f7351890da255482bae1cc587de78/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/healthcare.jpg?locale=us)
Why Novartis Stock Spiked Today
Novartis (NYSE: NVS) enjoyed a strong rally today, as the Swiss drugmaker announced an improved revenue forecast for 2023 and a massive share repurchase program. Specifically, the drugmaker's stock
![Novartis Ag (NVS) Q2 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Novartis Ag (NVS) Q2 2023 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q2 2023 Earnings CallJul 18, 2023, 8:00 a.m. ET
Operator
Source Fool.com
![Why Novartis Stock Slipped on Friday: https://g.foolcdn.com/editorial/images/738999/medical-professional-with-hand-on-head.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMnBIYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5076d84387ea3f578828c37f4fbf069be58002eb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professional-with-hand-on-head.jpg?locale=us)
Why Novartis Stock Slipped on Friday
Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical
![Why Shares of Vera Therapeutics Jumped Tuesday: https://g.foolcdn.com/editorial/images/736985/radiologist-of-oncology-institute-is-examing-mri-scans.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWsyYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--cc35a5f92766b15851792a411ac4d6a1882cab5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/radiologist-of-oncology-institute-is-examing-mri-scans.jpg?locale=us)
Why Shares of Vera Therapeutics Jumped Tuesday
Shares of Vera Therapeutics (NASDAQ: VERA) closed 16.9% higher on Tuesday after jumping as much as 23.5%. The clinical-stage biotech company announced positive news regarding trial results for one
![Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions: https://g.foolcdn.com/editorial/images/736519/a-customer-shops-at-a-pharmacy.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDgwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ae19a7f2340b90932e7519809b00477f7de74c07/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-customer-shops-at-a-pharmacy.jpg?locale=us)
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to
![Why Shares of Chinook Therapeutics Skyrocketed On Monday: https://g.foolcdn.com/editorial/images/736034/a-scientist-uses-a-pipette-to-work-with-medical-samples-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVl0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9f2171c52d3e9b6b1f4207ea72b66e184243e84e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-scientist-uses-a-pipette-to-work-with-medical-samples-1.jpg?locale=us)
Why Shares of Chinook Therapeutics Skyrocketed On Monday
Shares of Chinook Therapeutics (NASDAQ: KDNY) were up more than 57% early Monday afternoon after the healthcare company agreed to a $3.2 billion buyout offer from Novartis.
Chinook is a
![Is Novartis a Good Stock to Buy Right Now?: https://g.foolcdn.com/editorial/images/735483/pills-dollar-symbol.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFFvYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--56cd7ba9eb7bc9a4257aebe8d5a8ebaefb512f38/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pills-dollar-symbol.jpg?locale=us)
Is Novartis a Good Stock to Buy Right Now?
Novartis (NYSE: NVS) is a company in transition. Over the past several years, the Swiss multinational pharma giant has been busy divesting key assets such as its eye care unit Alcon, trimming costs
![Why Analog Devices Stock Was Down This Week: https://g.foolcdn.com/editorial/images/734109/modern-electronics-research-development-facility-engineer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2diYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d0cf1327953e2ea41e37f815ecb89d17b6d469e0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/modern-electronics-research-development-facility-engineer.jpg?locale=us)
Why Analog Devices Stock Was Down This Week
Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's
![Why Shares of Rain Oncology Are Plummeting Today: https://g.foolcdn.com/editorial/images/733498/nurses-station-in-hospital.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL29WYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5790c6fb95cc1220e70a8e261049c756c15f9674/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/nurses-station-in-hospital.jpg?locale=us)
Why Shares of Rain Oncology Are Plummeting Today
Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated
![Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024
![Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved
![Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon
![Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports
![Lonza Appoints Wolfgang Wienand as New Chief Executive Officer](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Lonza Appoints Wolfgang Wienand as New Chief Executive Officer
![Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche
![Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza
![Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
![Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
![Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
![Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
![Board Announcement](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)